JP2017508466A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508466A5
JP2017508466A5 JP2016555705A JP2016555705A JP2017508466A5 JP 2017508466 A5 JP2017508466 A5 JP 2017508466A5 JP 2016555705 A JP2016555705 A JP 2016555705A JP 2016555705 A JP2016555705 A JP 2016555705A JP 2017508466 A5 JP2017508466 A5 JP 2017508466A5
Authority
JP
Japan
Prior art keywords
item
car
seq
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555705A
Other languages
English (en)
Japanese (ja)
Other versions
JP6422134B2 (ja
JP2017508466A (ja
Filing date
Publication date
Priority claimed from GB201403972A external-priority patent/GB201403972D0/en
Application filed filed Critical
Publication of JP2017508466A publication Critical patent/JP2017508466A/ja
Publication of JP2017508466A5 publication Critical patent/JP2017508466A5/ja
Application granted granted Critical
Publication of JP6422134B2 publication Critical patent/JP6422134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555705A 2014-03-06 2015-03-06 キメラ抗原受容体 Active JP6422134B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201403972A GB201403972D0 (en) 2014-03-06 2014-03-06 Chimeric antigen receptor
GB1403972.1 2014-03-06
PCT/GB2015/050649 WO2015132604A1 (en) 2014-03-06 2015-03-06 Chimeric antigen receptor

Publications (3)

Publication Number Publication Date
JP2017508466A JP2017508466A (ja) 2017-03-30
JP2017508466A5 true JP2017508466A5 (https=) 2018-07-26
JP6422134B2 JP6422134B2 (ja) 2018-11-14

Family

ID=50554626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016555705A Active JP6422134B2 (ja) 2014-03-06 2015-03-06 キメラ抗原受容体

Country Status (20)

Country Link
US (3) US10975162B2 (https=)
EP (4) EP3241851A1 (https=)
JP (1) JP6422134B2 (https=)
KR (1) KR101965040B1 (https=)
CN (1) CN106536563B (https=)
AU (1) AU2015225950B2 (https=)
CA (1) CA2941159C (https=)
CL (1) CL2016002196A1 (https=)
DK (1) DK3114147T3 (https=)
ES (1) ES2673123T3 (https=)
GB (1) GB201403972D0 (https=)
HU (1) HUE038625T2 (https=)
MX (1) MX360707B (https=)
NZ (1) NZ723471A (https=)
PL (1) PL3114147T3 (https=)
PT (1) PT3114147T (https=)
RU (1) RU2685479C2 (https=)
SG (1) SG11201606790XA (https=)
TR (1) TR201807939T4 (https=)
WO (1) WO2015132604A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
SG10202012157QA (en) 2016-06-07 2021-01-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
US20190263928A1 (en) * 2016-09-30 2019-08-29 Baylor College Of Medicine Adaptive chimeric antigen receptor t-cell design
CN110461881B (zh) * 2017-03-27 2023-06-23 诺伊尓免疫生物科技株式会社 嵌合抗原受体
US20200101108A1 (en) * 2017-03-31 2020-04-02 The Board Of Trustees Of The Le-Land Standford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
IT201800003464A1 (it) * 2018-03-13 2019-09-13 Ospedale Pediatrico Bambino Gesu Cellule T CAR-CD30 per il trattamento di tumori CD30+
WO2019243817A1 (en) 2018-06-19 2019-12-26 Autolus Limited Cell
US20210322473A1 (en) * 2018-07-18 2021-10-21 The General Hospital Corporation Modified t cells and methods of their use
CN108864307A (zh) * 2018-07-23 2018-11-23 北京多赢时代科技有限公司 信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用
CN108948211B (zh) 2018-07-24 2021-08-20 北京美康基免生物科技有限公司 一种基于靶向gd2的嵌合抗原受体及其应用
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
CN109136244A (zh) * 2018-08-31 2019-01-04 河北璋达生物科技有限公司 一种可诱导凋亡的携带检测标签的cd20嵌合抗原受体t淋巴细胞及其应用
CN109096405B (zh) * 2018-09-20 2021-07-09 杭州普略生物科技有限公司 以gd2为靶点的嵌合抗原受体及药物组合物
CN113194966A (zh) 2018-10-03 2021-07-30 柰裴斯生命科学公司 抗cd79抗体及其应用
WO2020156335A1 (zh) * 2019-01-29 2020-08-06 上海交通大学 一种嵌合抗原受体及其应用
CA3130671A1 (en) * 2019-02-07 2020-08-13 Board Of Regents, The University Of Texas Systems Glucuronoxylomannan (gxm) receptor chimeric antigen receptors and use thereof
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
SG11202111031RA (en) 2019-04-26 2021-11-29 Allogene Therapeutics Inc Rituximab-resistant chimeric antigen receptors and uses thereof
EP4008347B1 (en) * 2019-08-01 2025-04-30 Mie University GD2-BINDING MOLECULE
WO2021081133A1 (en) * 2019-10-21 2021-04-29 Purdue Research Foundation Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
US20220411535A1 (en) * 2019-11-26 2022-12-29 University Of Utah Research Foundation Compositions and methods for upregulating hla class i on tumor cells
AU2021252514B2 (en) * 2020-04-06 2025-06-26 Lung Biotechnology Pbc Modular synthetic receptors and methods of use
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
WO2023139360A1 (en) 2022-01-19 2023-07-27 Autolus Limited Nucleic acid construct
CN119095881A (zh) * 2022-03-25 2024-12-06 豪夫迈·罗氏有限公司 经改善的嵌合受体
CA3247582A1 (en) * 2022-04-18 2023-10-26 Wisconsin Alumni Research Foundation COMBINATIONAL IMMUNOTHERAPIES INVOLVING CAR-M, CAR-NK, CAR-EOS AND CAR-N CELLS
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
CN117024605B (zh) * 2023-08-15 2024-01-09 北京市眼科研究所 嵌合抗原受体、表达嵌合抗原受体的小胶质细胞及其应用
WO2025035762A1 (zh) * 2023-08-15 2025-02-20 北京市眼科研究所 嵌合抗原受体、表达嵌合抗原受体的小胶质细胞及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023573A1 (fr) * 1999-09-30 2001-04-05 Kyowa Hakko Kogyo Co., Ltd. Anticorps transplantes a domaine de determination de complementation de type humain, dresse contre le ganglioside gd2, et derive de cet anticorps
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
FR2906808B1 (fr) * 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
EP3323830B1 (en) * 2010-06-19 2023-08-23 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103946952A (zh) * 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
EP3326467B1 (en) * 2011-09-16 2020-03-11 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
CN103145849B (zh) 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
MX373687B (es) 2013-11-21 2020-07-07 Ucl Business Ltd Célula natural (nk)
DK3241561T3 (da) 2014-03-05 2025-06-30 Autolus Ltd Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor

Similar Documents

Publication Publication Date Title
JP2017508466A5 (https=)
RU2016138422A (ru) Химерный антигенный рецептор
JP2018508215A5 (https=)
JP2017500869A5 (https=)
JP2018527919A5 (https=)
JP2016508725A5 (https=)
JP2019530431A5 (https=)
JP2016537966A5 (https=)
JP2016538830A5 (https=)
US20210177951A1 (en) Engineered cells & methods
JP2018531014A5 (https=)
RU2015139874A (ru) ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
JP2019511222A5 (https=)
JP2016513467A5 (https=)
JP2013538057A5 (https=)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
JP2011514150A5 (https=)
JP2019502676A5 (https=)
JP2018501794A5 (https=)
JP2015527070A5 (https=)
JP2014531201A5 (https=)
JP2016520074A5 (https=)
JP2019500894A5 (https=)
JP2017537627A5 (https=)
RU2017121892A (ru) Клетка